A Double Blind, Randomised, Placebo-controlled, Multiple Ascending-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DS 1093a in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
Price : $35 *
At a glance
- Drugs DS 1093 (Primary)
- Indications Anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 13 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 May 2014 New trial record